- Larazotide is a tight junction regulator
- The drug is also in Ph III trials for celiac disease
- The FDA awarded fast track status to Larazotide for celiac
- If approved... read more
BPU Holdings... read more
... read more
Galecto Biotech AB, the leading developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, today announced the successful closing of a €79 million series... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,